Design Therapeutics, Inc.·4

Jun 11, 4:15 PM ET

Berger Heather A. 4

Research Summary

AI-generated summary

Updated

Design Therapeutics Director Heather Berger Receives 30,000-Share Award

What Happened

  • Heather A. Berger, a director of Design Therapeutics, was granted a derivative award covering 30,000 shares on June 9, 2026. The Form 4 reports the acquisition at $0.00 (derivative), indicating an option/award rather than an open-market purchase or sale. No cash changed hands at filing.

Key Details

  • Transaction date: June 9, 2026; Form 4 filed June 11, 2026 (timely filing).
  • Amount: 30,000 shares (derivative award/option); reported price $0.00 on the Form 4.
  • Vesting: Shares subject to the option vest in equal monthly installments over 12 months beginning June 9, 2026, and will be fully vested by the company's next annual meeting of stockholders (per footnote).
  • Shares owned after transaction: Not provided in the supplied filing excerpt.
  • Filing status: Not marked late.

Context

  • This was a grant/award (an acquisition of a derivative interest), not a sale. Derivative grants (options or RSUs) confer the right to receive shares over time and do not represent immediate sale proceeds or open-market buying. Such grants are commonly used for director compensation and should be interpreted as part of pay, not necessarily a direct buy/sell signal.